Wang, Y., Tong, C., Dai, H., Wu, Z., Han, X., Guo, Y., . . . Han, W. (2021). Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nature communications, 12(1), 409-18. https://doi.org/10.1038/s41467-020-20696-x
Citace podle Chicago (17th ed.)Wang, Yao, et al. "Low-dose Decitabine Priming Endows CAR T Cells with Enhanced and Persistent Antitumour Potential via Epigenetic Reprogramming." Nature Communications 12, no. 1 (2021): 409-18. https://doi.org/10.1038/s41467-020-20696-x.
Citace podle MLA (9th ed.)Wang, Yao, et al. "Low-dose Decitabine Priming Endows CAR T Cells with Enhanced and Persistent Antitumour Potential via Epigenetic Reprogramming." Nature Communications, vol. 12, no. 1, 2021, pp. 409-18, https://doi.org/10.1038/s41467-020-20696-x.